Based on these rates of growth, Norton argued that giving the same total dose of chemotherapy over a shorter period of time would boost the cure rate by limiting the time tumors could regrow between treatments.
Against that background, the doubling of DM610 jobs over the past decade to a current total of 5.6m looks less like a curse and more like a signpost to a cure.